drugset / Trial / NCT03782064
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Phase 2
Terminated
5 enrolled
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb · collabDana-Farber Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma (MM). The drugs involved in this study are: * Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) * Nivolumab, an immunotherapy drug
Timeline
- Start
- 2019-02-22
- Primary completion
- 2021-01-31
- Completion
- 2021-01-31
Outcome
Outcome not reported
Stopped (Business): “Funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC/myeloma fusions | Vaccine | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Background | GM-CSF | Protein / enzyme biologic | — | — |